Patients’ baseline characteristics at the time of sampling
| Parameter . | Category . | CLL, n = 406 . |
|---|---|---|
| Sex | % Male/Female | 57/43 |
| Age, y | Median (range) | 66 (19-94) |
| Time from diagnosis to sampling, mo | <12 | 206 |
| >12 | 200 | |
| Binet stage | A | 313 |
| B | 52 | |
| C | 15 | |
| Unknown | 26 | |
| Rai stage | 0 | 253 |
| I-II | 109 | |
| III-IV | 17 | |
| Unknown | 27 | |
| CNAs | Trisomy 12 | 52/376 (13.8%) |
| Del13q | 163/376 (43.4%) | |
| Del17p | 19/398 (4.7%) | |
| Del11q | 36/398 (9.0%) | |
| IGHV mutational status | Mutated | 218/382 (57.1%) |
| Patients treated during follow-up | n (%) | 208/406 (51.2%) |
| Follow-up from sampling, mo | Median (range) | 35 (6-224) |
| Parameter . | Category . | CLL, n = 406 . |
|---|---|---|
| Sex | % Male/Female | 57/43 |
| Age, y | Median (range) | 66 (19-94) |
| Time from diagnosis to sampling, mo | <12 | 206 |
| >12 | 200 | |
| Binet stage | A | 313 |
| B | 52 | |
| C | 15 | |
| Unknown | 26 | |
| Rai stage | 0 | 253 |
| I-II | 109 | |
| III-IV | 17 | |
| Unknown | 27 | |
| CNAs | Trisomy 12 | 52/376 (13.8%) |
| Del13q | 163/376 (43.4%) | |
| Del17p | 19/398 (4.7%) | |
| Del11q | 36/398 (9.0%) | |
| IGHV mutational status | Mutated | 218/382 (57.1%) |
| Patients treated during follow-up | n (%) | 208/406 (51.2%) |
| Follow-up from sampling, mo | Median (range) | 35 (6-224) |
Del, deletion; IGHV unmutated, ≥98% identity with germ line.